论文部分内容阅读
目的观察国产多西紫杉醇联合顺铂治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的近期疗效和不良反应。方法采用DP方案化疗:多帕菲75mg/m2,静脉滴注,第1天;顺铂75mg/m2,静脉滴注,第1天;21d为1个周期。至少使用2个周期评价疗效。结果70例中CR2例,PR29例,SD36例,PD3例,总有效率为44.3%。中位TTP6.3个月,中位生存期10.1个月,1年生存率38.6%。不良反应主要为骨髓抑制、脱发和消化系统反应,骨髓抑制为剂量限制性毒性,其中白细胞减少占75.7%。结论国产多西紫杉醇联合顺铂治疗晚期NSCLC近期疗效较好,毒不良反应较轻,值得临床进一步推广应用。
Objective To observe the short-term efficacy and side effects of domestic docetaxel combined with cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC). Methods DP chemotherapy: docetaxel 75mg / m2, intravenous drip, the first day; cisplatin 75mg / m2, intravenous drip, the first day; 21d for a cycle. Use at least 2 cycles to evaluate efficacy. Results 70 cases of CR2 cases, PR29 cases, SD36 cases, PD3 cases, the total effective rate was 44.3%. Median TTP 6.3 months, the median survival of 10.1 months, 1-year survival rate of 38.6%. Adverse reactions were mainly myelosuppression, alopecia and digestive system reactions, and myelosuppression was dose-limiting toxicity, with leukopenia accounting for 75.7%. Conclusion Domestic docetaxel combined with cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC) has better curative effect and less toxic side effects. It is worth further clinical application.